RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naïve Patients with HIV
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 19
OP 21
DO 10.1177/155989771428012
UL http://mdc.sagepub.com/content/14/28/19.abstract
AB Results from a 48-week, open-label extension of A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla [SINGLE, NCT01263015], a phase 3, randomized, double-blind trial, have reaffirmed week 48 and week 96 results [Walmsley SL et al. N Engl J Med. 2013] of the superiority of once-daily dolutegravir 50 mg used with abacavir/lamivudine compared with efavirenz/tenofovir/emtricitabine in treatment-naïve patients with HIV-1.